Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors

Abstract

Recent studies have demonstrated enhanced anticancer effects of combination therapy consisting of camptothecin derivatives and HDAC inhibitors. To exploit this synergy in a single active compound, we designed new dual-acting multivalent molecules simultaneously targeting topoisomerase I and HDAC. In particular, a selected compound containing a camptothecin and the psammaplin A scaffold showed a broad spectrum of antiproliferative activity, with IC₅₀ values in the nanomolar range. Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.

Keywords: Antiproliferative activity; Antitumor activity; Camptothecin; Dual-action inhibitors; HDAC inhibitors; Psammaplin.